Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01027949 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 894
- Enrollment target
NCT01027949 is a Phase 3 study that has completed, run by United Therapeutics. The registered enrollment target is 894 participants.
The verdict
NCT01027949, a Phase 3 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 894 participants
- Enrollment target
Study Summary
This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308. The study assessed the long term safety of oral treprostinil and the effect of continued treatment with oral treprostinil on exercise capacity after 1 year of treatment.
Interventions
- DRUG Oral Treprostinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 894 participants |
| Start Date | 2007-01-16 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01027949
The ClinicalTrials.gov registry entry for NCT01027949 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 894 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral Treprostinil is the first listed.
NCT01027949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01027949 about?
NCT01027949 is a clinical study titled "An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension". This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308. The study assessed the long term safety of oral treprostinil and the effect...
What is the current status of trial NCT01027949?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 894 participants. The study started on 2007-01-16. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT01027949?
The interventions under investigation include: Oral Treprostinil (DRUG).
Who is sponsoring clinical trial NCT01027949?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.